Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Operating Expenses (2016 - 2026)

Organogenesis Holdings has reported Operating Expenses over the past 10 years, most recently at $431.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 270.91% year-over-year to $431.9 million; the TTM value through Dec 2025 reached $671.4 million, up 47.68%, while the annual FY2025 figure was $519.5 million, 7.48% up from the prior year.
  • Operating Expenses for Q4 2025 was $431.9 million at Organogenesis Holdings, up from $36.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $431.9 million in Q4 2025 and troughed at -$134.5 million in Q4 2023.
  • A 5-year average of $91.9 million and a median of $82.0 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: crashed 268.79% in 2023 and later skyrocketed 270.91% in 2025.
  • Year by year, Operating Expenses stood at $75.5 million in 2021, then rose by 5.53% to $79.7 million in 2022, then crashed by 268.79% to -$134.5 million in 2023, then skyrocketed by 186.57% to $116.4 million in 2024, then skyrocketed by 270.91% to $431.9 million in 2025.
  • Business Quant data shows Operating Expenses for ORGO at $431.9 million in Q4 2025, $36.3 million in Q3 2025, and $113.6 million in Q2 2025.